先期化疗在晚期卵巢癌中的临床应用与疗效评价  

Efficacy of neoadjuvant chemotherapy in advanced ovarian cancer

作　　者：吴笑颜[1] 

机构地区：[1]广西百色市人民医院妇科,广西百色533000

出　　处：《实用肿瘤杂志》2012年第6期650-652,共3页Journal of Practical Oncology

摘　　要：目的探讨在晚期卵巢癌患者中行先期化疗的临床疗效。方法 130例晚期卵巢癌患者随机分为新辅助化疗组及术后化疗组,各65例,比较两组患者临床资料差异性。结果新辅助化疗组手术时间(180±15)分钟,术后化疗组(240±25)分钟;新辅助化疗组出血量(380±55)mL,术后化疗组(610±80)mL;新辅助化疗组较术后化疗组术后并发症少8例,新辅助化疗组较术后化疗组缓解满意率高29.2%,1年生存率高15.4%,3年生存率高21.6%,差异均有统计学意义(P<0.05)。结论先期化疗具有手术时间短、出血量少、术后并发症少、提高缓解率、延长生存率的优点。Objective To evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced ovarian cancer.Methods One hundred and thirty patients with advanced ovarian cancer were randomly divided into neoadjuvant chemotherapy and postoperative chemotherapy groups with 65 cases in each group.The clinical data were compared between two groups.Results The operation time was（180 ± 15） min and（240 ± 25） min,and the blood loss was（380 ± 55） mL and（610 ± 80） mL in neoadjuvant chemotherapy group and postoperative chemotherapy group,respectively.Neoadjuvant chemotherapy group had 8 less cases with postoperative complications than postoperative chemotherapy group.The satisfaction rate and the 1y-,3y-survival rates in neoadjuvant group were 29.2%,and 15.4%,21.6% higher than those in postoperative group,respectively（all P 0.05）.Conclusion Neoadjuvant chemotherapy has shorter operation time,less bleeding,less postoperative complications,and higher satisfaction and survival rate than postoperative chemotherapy for patients with advanced ovarian cancer.

关 键 词：卵巢肿瘤 药物疗法 卵巢肿瘤 外科学 化学疗法 辅助 手术后期间 存活率 病例对照研究 

分 类 号：R737.31[医药卫生—肿瘤]